📊 SLNO Key Takeaways
Is Soleno Therapeutics Inc. (SLNO) a Good Investment?
SLNO demonstrates exceptional financial strength with $133M cash, excellent liquidity (5.62x current ratio), and strong profitability margins (33.2% net margin). However, negative gross profit is a critical concern requiring clarification on cost structure, production ramping, or revenue mix changes in the pharmaceutical sector.
Soleno Therapeutics Inc. Key Strengths (SLNO)
- Exceptional balance sheet with 495.8M equity and low leverage (0.10x debt/equity)
- Strong operating margins of 33.1% with positive net income of 31.4M and growing EPS
- Excellent liquidity position: 5.62x current ratio, 133M cash, and 25.9M positive free cash flow
- Conservative capital structure with 24.2x interest coverage ratio and minimal capex requirements
SLNO Stock Risks: Soleno Therapeutics Inc. Investment Risks
- Negative gross profit of -38K with 0.0% gross margin is highly unusual for pharma and indicates structural cost issues
- Revenue growth of 13,024% YoY is unsustainable and suggests one-time event (product launch, acquisition, milestone)
- Modest returns on capital (ROE 6.3%, ROA 5.2%) suggest capital deployment inefficiency despite strong absolute earnings
- Pharmaceutical sector exposure carries inherent regulatory, clinical, and commercial execution risks
Key Metrics to Watch
- Gross profit margin sustainability and recovery trajectory
- Revenue growth normalization and organic growth rate going forward
- Return on equity and return on assets improvement with revenue scale
- Operating cash flow trend relative to net income and capital allocation decisions
Soleno Therapeutics Inc. (SLNO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 27.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.62x current ratio provides a solid financial cushion.
SLNO Profit Margin, ROE & Profitability Analysis
SLNO vs Healthcare Sector: How Soleno Therapeutics Inc. Compares
How Soleno Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Soleno Therapeutics Inc. Stock Overvalued? SLNO Valuation Analysis 2026
Based on fundamental analysis, Soleno Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Soleno Therapeutics Inc. Balance Sheet: SLNO Debt, Cash & Liquidity
SLNO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Soleno Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
SLNO Revenue Growth, EPS Growth & YoY Performance
SLNO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $94.6M | $31.4M | $0.59 |
| Q3 2025 | $66.0M | -$4.7M | $-0.45 |
| Q2 2025 | $32.7M | -$4.7M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Soleno Therapeutics Inc. Dividends, Buybacks & Capital Allocation
SLNO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Soleno Therapeutics Inc. (CIK: 0001484565)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 18, 2026 | 4 | xslF345X06/form4-05182026_080544.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_080510.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_080529.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_080531.xml | View → |
| May 18, 2026 | 4 | xslF345X06/form4-05182026_080545.xml | View → |
❓ Frequently Asked Questions about SLNO
What is the AI rating for SLNO?
Soleno Therapeutics Inc. (SLNO) has an AI grade of A with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLNO's key strengths?
Claude: Exceptional balance sheet with 495.8M equity and low leverage (0.10x debt/equity). Strong operating margins of 33.1% with positive net income of 31.4M and growing EPS.
What are the risks of investing in SLNO?
Claude: Negative gross profit of -38K with 0.0% gross margin is highly unusual for pharma and indicates structural cost issues. Revenue growth of 13,024% YoY is unsustainable and suggests one-time event (product launch, acquisition, milestone).
What is SLNO's revenue and growth?
Soleno Therapeutics Inc. reported revenue of $94.6M.
Does SLNO pay dividends?
Soleno Therapeutics Inc. does not currently pay dividends.
Where can I find SLNO SEC filings?
Official SEC filings for Soleno Therapeutics Inc. (CIK: 0001484565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLNO's EPS?
Soleno Therapeutics Inc. has a diluted EPS of $0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SLNO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Soleno Therapeutics Inc. has a A grade with 62% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is SLNO stock overvalued or undervalued?
Valuation metrics for SLNO: ROE of 6.3% (sector avg: 15%), net margin of 33.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SLNO's AI grade for 2026?
Our dual AI analysis gives Soleno Therapeutics Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SLNO's free cash flow?
Soleno Therapeutics Inc.'s operating cash flow is $26.0M, with capital expenditures of $40.0K. FCF margin is 27.4%.
How does SLNO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 33.2% (avg: 12%), ROE 6.3% (avg: 15%), current ratio 5.62 (avg: 2).